ProMetic Life Sciences Inc. (PLI) 2007年年度报告「TSX」.pdf

1、Therapeutics to treatrare bleeding disordersTherapeutics to treat anemia&neutropeniaExtraction&recovery of plasma-derived therapeutic proteinsPathogen removal from blood ProMetic Life Sciences Inc.2007 Annual Report(we areInnovatorsProMetics world-leading expertise in blood fractionation and affinit

2、y separation is used by life sciences companies of all sizes to facilitate their drug development and manufacturing processes.PROMETIC LIFE SCIENCES INC.FRONT COVER:THE BUSINESS OF PROMETIC IS PRIMARILY RELATED TO THE FUNDAMENTAL SUBSTANCE OF LIFE.PROMETICS TECHNOLOGIES ARE USED TO REMOVE PATHOGENS

3、FROM BLOOD,AND EXTRACT AND RECOVER VALUABLE PROTEINS FROM PLASMA.PROMETIC DEVELOPS THERAPEUTICS TO TREAT BLOOD-RELATED DISORDERS.PROMETIC IS A WORLD-LEADING TECHNOLOGY PROVIDER AND DRUG DEVELOPER IN THE FIELDS OF HEMATOLOGY,ONCOLOGY AND NEPHROLOGY.Contents Signifi cant events Page 2 Message to Share

4、holders Page 6 Protein Technologies Page 14 Therapeutics Page 18 Managements Discussion&Analysis Page 21 Consolidated Financial Statements Page 33CreatorsProMetic has originated first-in-class synthetic compounds to address massive unmet medical needs involving blood disorders and cancer.DevelopersP

5、roMetic has steadily advanced PBI-1402,its high-value candidate drug,through the clinical trial process,while leveraging its technologies and partnerships to deepen and extend its product pipeline.ProMetic Life Sciences Inc.1Signifi cant EventsLicencing agreement with Tecpar of Brazil for biopharmac

6、eutical )product-value to ProMetic of$11 MStrategic alliance with Blue Blood of Taiwan for plasma-derived )therapeutics;primary markets are Taiwan and Southeast AsiaDevelopment contract signed with a prominent European plasma )fractionation company for prion removal process in plasma-transaction wor